Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:6235618.
doi: 10.1155/2016/6235618. Epub 2016 Mar 23.

Primary Multidrug Resistant Tuberculosis and Utility of Line Probe Assay for Its Detection in Smear-Positive Sputum Samples in a Tertiary Care Hospital in South India

Affiliations

Primary Multidrug Resistant Tuberculosis and Utility of Line Probe Assay for Its Detection in Smear-Positive Sputum Samples in a Tertiary Care Hospital in South India

Fahmiya Leena Yacoob et al. J Pathog. 2016.

Abstract

In a high tuberculosis burdened country like India, rapid, cost-effective, and reliable diagnostic tools for tuberculosis are an urgent need of the hour to prevent inappropriate treatment strategies and further spread of resistance. This study aimed to estimate the proportion of new smear-positive tuberculosis cases with primary resistance to rifampicin and/or isoniazid as well as identify the common mutations associated with it. Sputum of 200 newly diagnosed smear-positive cases of 1+ score and above was directly subjected to Line Probe Assay using the GenoType MTBDRplus assay kit. All samples were inoculated onto solid media and 61 samples were inoculated in automated liquid culture also. The Line Probe Assay gave hundred percent interpretable results with 2.5% of the study population showing resistant pattern. Only 1% of the cases were primary multidrug resistant tuberculosis and 1.5% showed isoniazid monoresistance. S531L and C15T were the most common genetic mutations seen for rifampicin and isoniazid resistance, respectively. 40% had absent rpoB wild type 8 band indicating probable silent mutation after clinical correlation. The average turnaround time for Line Probe Assay was far less (3.8 days) as compared to solid and liquid cultures (35.6 days and 13.5 days, resp.).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Negative control with CC and AC bands. The red band is reference marker to align the strip.
Figure 2
Figure 2
Patient with MDR TB showing presence of rpoB MUT3 band and inhA MUT1 band along with the wild type bands indicating rifampicin resistance and INH heteroresistance, respectively.
Figure 3
Figure 3
(From left to right) Lane 1: sensitive pattern. Lane 2: MDR TB patient with rpoB MUT3 band indicating rifampicin resistance and katG MUT1 band and inhA MUT3A band along with wild type band indicating INH heteroresistance. Lane 3: reference strip.
Figure 4
Figure 4
Patient with inhA MUT1 band along with wild type bands indicating low level INH heteroresistance.
Figure 5
Figure 5
Patient showing low level INH monoresistance with absent inhA WT1 band and presence of inhA MUT1 band.
Figure 6
Figure 6
(From left to right) Lane 1: faint rpoB WT8 band interpreted as sensitive pattern. Lanes 2 and 3: sensitive pattern. Lane 4: sensitive pattern with absent rpoB WT8 band.
Figure 7
Figure 7
Age and gender distribution of the study population. The majority of the patients are of the age group between 41 and 50 with male preponderance.

Similar articles

Cited by

References

    1. World Health Organization. Global Tuberculosis Report 2015. Geneva, Switzerland: World Health Organization; 2015.
    1. Regional Office for South-East Asia. Tuberculosis in South East Asia Region, Annual TB Report 2015. New Delhi, India: World Health Organization-SEAR; 2015.
    1. Drug-Resistant TB. Global TB Report. Geneva, Switzerland: World Health Organization; 2014. Surveillance and response, supplement.
    1. WHO. Policy Statement. WHO; 2008. Molecular line probe assays for rapid screening of patients at risk of MDR-TB. http://www.who.int/tb/features_archive/policy_statement.pdf.
    1. TB India. Revised National Tuberculosis Control Programme Annual Status Report. New Delhi, India: Government of India; 2014.

LinkOut - more resources